High glucose reduces generation of plasmin activity by mesangial cells

E J Fisher1, S V McLennan, D K Yue

  • 1Department of Medicine, University of Sydney, New South Wales, Australia.

Insights

High glucose impairs mesangial cell function in diabetic nephropathy by reducing plasmin generation. This contributes to decreased extracellular matrix degradation, a key factor in kidney disease progression.

Area of Science:

  • Nephrology
  • Cell Biology
  • Biochemistry

Background:

  • Mesangial enlargement is a hallmark of diabetic nephropathy.
  • Reduced mesangium degradation occurs in high glucose environments.
  • Plasmin is crucial for extracellular matrix degradation.

Purpose of the Study:

  • To investigate the effect of high glucose on the plasminogen cascade in mesangial cells.
  • To determine if high glucose impairs mesangial cell plasmin generation.

Main Methods:

  • Cultured human mesangial cells were exposed to high glucose concentrations.
  • Analysis of plasminogen cascade components (plasminogen, urokinase-type plasminogen activator, tissue-type plasminogen activator, plasminogen activator inhibitor-1) on cell surface and associated with cells.
  • Measurement of mesangial cell plasmin activity generation.

Main Results:

  • High glucose decreased plasminogen and urokinase-type plasminogen activator binding to mesangial cells.
  • High glucose increased tissue-type plasminogen activator and plasminogen activator inhibitor-1 associated with mesangial cells.
  • Overall reduction in mesangial cell plasmin activity generation under high glucose conditions.

Conclusions:

  • High glucose significantly alters the plasminogen cascade on mesangial cells.
  • This alteration leads to reduced plasmin generation capacity in a high glucose milieu.
  • The impaired plasmin activity may explain reduced mesangium degradation in diabetic nephropathy.

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...